

In the Claims:

Please amend the claims as follows:

1. -23. (Canceled).
24. (Currently Amended) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt or solvate thereof.
25. (Previously Presented) The compound as claimed in claim 24 in nanoparticulate form.
26. (Previously Presented) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.
27. (Previously Presented) The compound as claimed in claim 26 in nanoparticulate form.
28. (Currently Amended) A pharmaceutical composition comprising 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt or solvate thereof.
29. (Previously Presented) The pharmaceutical composition as claimed in claim 28 further comprising a pharmaceutical carrier or diluent thereof.
30. (Previously Presented) The pharmaceutical composition as claimed in claim 29 further comprising a second therapeutic agent.
31. (Previously Presented) The pharmaceutical composition as claimed in claim 28 wherein the compound is in nanoparticulate form.

32. (Previously Presented) The pharmaceutical composition as claimed in claim 31 further comprising a pharmaceutical carrier or diluent thereof.
33. (Previously Presented) A pharmaceutical composition comprising 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.
34. (Previously Presented) The pharmaceutical composition as claimed in claim 33 further comprising a pharmaceutical carrier or diluent thereof.
35. (Previously Presented) The pharmaceutical composition as claimed in claim 34 further comprising a second therapeutic agent.
36. (Previously Presented) The pharmaceutical composition as claimed in claim 33 wherein the compound is in nanoparticulate form.
37. (Previously Presented) The pharmaceutical composition as claimed in claim 36 further comprising a pharmaceutical carrier or diluent thereof.
38. (Previously Presented) The pharmaceutical composition as claimed in claim 37 further comprising a second therapeutic agent.
39. (Currently Amended) A method of treating a human or animal subject suffering from pain selected from the group consisting of inflammatory pain, visceral pain, cancer pain, neuropathic pain, post operative pain, acute pain, rheumatoid arthritic pain, and osteoarthritic pain, ~~a condition selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis,~~ which comprises administering to said subject a therapeutically effective amount of 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt or solvate thereof.

40. (Previously Presented) The method claimed claim 39 wherein the condition is osteoarthritic pain ~~pain selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine.~~

41. (Canceled).

42. (Currently Amended) A method of treating a human or animal subject suffering from ~~a condition selected from~~ an inflammatory bowel disease ~~an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis,~~ which comprises administering to said subject a therapeutically effective amount of 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable salt thereof.

43. (Canceled).

44. (Currently Amended) The method as claimed claim 42 wherein the inflammatory bowel disease ~~condition is an inflammatory disorder selected from the group consisting of~~ Crohn's disease ; and ulcerative colitis ~~or inflammatory bowel disease.~~